Canadian supportive care recommendations for the management of anemia in patients with cancer

Current Oncology

Volumn 14, Issue 5, 2007, Pages 209-217

  Mikhael, J ^a   Melosky, B ^b   Cripps, C ^c   Rayson, D ^d   Kouroukis, C T ^e  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b BC Cancer Agency   (Canada)

^c OTTAWA REGIONAL CANCER CENTRE   (Canada)

^d QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^e JURAVINSKI CANCER CENTRE   (Canada)

Author keywords

Anemia; Canadian recommendations; Cancer; Chemotherapy induced anemia; CIA; Erythropoiesis stimulating agent; ESA; Iron; Safety; Supportive care

Indexed keywords

EID: 67749150832     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.2007.149     Document Type: Article

References (36)

1. Ludwig H, Van Belle S, Barrett-Lee P, et al. The European Cancer Anaemia Survey (ECAS): A large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 2004;40: 2293-306.
2. Littlewood TJ, Bajetta E, Nortier JW, Vercammen E, Rapoport B for the Epoetin Alfa Study Group. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001;19: 2865-74.
3. Witzig TE, Silberstein PT, Loprinzi CL, et al. Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy. J Clin Oncol 2005;23:2606-17.
4. Demetri GD, Kris M, Wade J, Degos L, Cella D for the Procrit Study Group. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: Results from a prospective community oncology study. J Clin Oncol 1998;16:3412-25.
5. Cella D. Factors influencing quality of life in cancer patients: Anemia and fatigue. Semin Oncol 1998;25(suppl 7):43-6.
6. Bohlius J, Wilson J, Seidenfeld J, et al. Recombinant human erythropoietins and cancer patients: Updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 2006; 98:708-14.
7. Rizzo JD, Lichtin AE, Woolf SH, et al. Use of epoetin in patients with cancer: Evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Blood 2002;100:2303-20.
8. Bokemeyer C, Aapro MS, Courdi A, et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. Eur J Cancer 2004;40:2201-16.
9. National Comprehensive Cancer Network (NCCN). Practice Guidelines in Oncology: Cancer- and Treatment-Related Anemia. Ver. 3. Jenkintown, PA: NCCN; 2007. [Available online at: Www.nccn.org/professionals/physician_gls/PDF/anemia.pdf;cited September 6, 2007]
10. Rodgers GM. Guidelines for the use of erythropoietic growth factors in patients with chemotherapy-induced anemia. Oncology 2006;20(suppl 6):12-15.
11. Bokemeyer C, Aapro MS, Courdi A, et al. EORTC guidelines for the use of erythropoietic proteins in anemic patients with cancer: 2006 update. Eur J Cancer 2007;43:258-70.
12. Janssen-Ortho Inc. Product Monograph: Eprex (Epoetin Alfa). Toronto: Janssen-Ortho; November 17, 2006.
13. Amgen Canada Inc. Aranesp (darbepoetin alfa) [product monograph]. Toronto: Amgen Canada; June 7, 2006.
14. Seidenfeld J, Piper M, Bohlius J, et al. Comparative Effectiveness of Epoetin and Darbepoetin for Managing Anemia in Patients Undergoing Cancer Treatment. Comparative Effectiveness Review No. 3. Rockville, MD: Agency for Healthcare Research and Quality; May 2006. [Available online at: Www.effectivehealthcare.ahrq.gov/reports/final.cfm; cited September 11, 2007]
15. Cheung W, Minton N, Gunawardena K. Pharmacokinetics and pharmacodynamics of epoetin alfa once weekly and three times weekly. Eur J Clin Pharmacol 2001;57:411-18.
16. Canon JL, Vansteenkiste J, Bodoky G, et al. Randomized, double-blind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia. J Natl Cancer Inst 2006;98:273-84.
17. Couture F, Turner AR, Melosky B, et al. Prior red blood cell transfusions in cancer patients increase the risk of subsequent transfusions with or without recombinant human erythropoietin management. Oncologist 2005;10:63-71.
18. Quirt I, Kovacs M, Couture F, et al. Patients previously transfused or treated with epoetin alfa at low baseline hemoglobin are at higher risk for subsequent transfusion: An integrated analysis of the Canadian experience. Oncologist 2006;11: 73-82.
19. Lyman GH, Glaspy J. Are there clinical benefits with early erythropoietic intervention for chemotherapy-induced anemia? A systematic review. Cancer 2006;106:223-33.
20. Glaspy J, Henry D, Patel R, et al. Effects of chemotherapy on endogenous erythropoietin levels and the pharmacokinetics and erythropoietic response of darbepoetin alfa: A randomized clinical trial of synchronous versus asynchronous dosing of darbepoetin alfa. Eur J Cancer 2005;41:1140-9.
21. Leyland-Jones B, Semiglazov V, Pawlicki M, et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: A survival study. J Clin Oncol 2005;23: 5960-72.
22. Henke M, Laszig R, Rube C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: Randomized, double-blind, placebo-controlled trial. Lancet 2003;362:1255-60.
23. Wright JR, Ung YC, Julian JA, et al. Randomized, doubleblind, placebo-controlled trial of erythropoietin in non-smallcell lung cancer with disease-related anemia. J Clin Oncol 2007;25:1027-32.
24. Crawford J, Robert F, Perry MC, Belani C, Williams D, for the Anemia Prevention in NSCLC Group. A randomized trial comparing immediate versus delayed treatment of anemia with once-weekly epoetin alfa in patients with non-small cell lung cancer scheduled to receive first-line chemotherapy. J Thorac Oncol 2007;2:210-20.
25. Vansteenkiste J, Pirker R, Massuti B, et al., for the Aranesp 980297 Study Group. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 2002;94: 1211-20.
26. Grote T, Allen A, Castillo R, et al. Efficacy and safety analysis of epoetin alfa in patients with small cell lung cancer: A randomized, double-blind, placebo-controlled trial. J Clin Oncol 2005;23:9377-86.
27. Pirker R, Ramlau R, Schuette W, et al. A phase 3 randomized, double blind, placebo-controlled study of patients with previously untreated extensive-stage small cell lung cancer (SCLC) treated with platinum plus etoposide chemotherapy with or without darbepoetin alfa: PD6-3-6. J Thorac Oncol 2007; 2:S433-4.
28. Bohlius J, Langensiepen S, Schwarzer G, et al. Recombinant human erythropoietin and overall survival in cancer patients: Results of a comprehensive meta-analysis. J Natl Cancer Inst 2005;97:489-98.
29. Henke M, Mattern D, Pepe M, et al. Do erythropoietin receptors on cancer cells explain unexpected clinical findings? J Clin Oncol 2006;24:4708-13.
30. United States, Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Oncologic Drugs Advisory Committee (ODAC). May 4, 2004, Meeting Transcript [starting at p. 155, l. 21: Presentation by Dr. Jens Overgaard, representing the Danish Head and Neck Cancer Group, of an interim analysis of DAHANCA 10]. Gaithersburg, MD: ODAC; 2004. [Available online at: Www.fda.gov/ohrms/dockets/ac/04/transcripts/4037T2.htm; cited September 6, 2007]
31. Sinclair AM, Todd MD, Forsythe K, Knox SJ, Elliott S, Begley CG. Expression and function of erythropoietin receptors in tumors: Implications for the use of erythropoiesis-stimulating agents in cancer patients. Cancer 2007;110:477-88.
32. Canada, Health Canada. Home > Drugs & Health Products >MedEffect > Advisories, Warnings & Recalls > Health Canada Endorsed Important Safety Information on Erythropoiesis-Stimulating Agents (ESAs): Aranesp (darbepoetin alfa) and Eprex (epoetin alfa) [Web page]. Toronto and Ottawa: Amgen Canada Inc., Janssen-Ortho Inc., and Health Canada; April 16, 2007. [Available at: Www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/2007/aranesp_eprex_hpc-cps_e.html]
33. Auerbach M, Ballard H, Trout JR, et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: A multicenter, open-label, randomized trial. J Clin Oncol 2004; 22:1301-7.
34. Vandebroek A, Gaede B, Altintas S, et al. A randomized openlabel study of darbepoetin alfa administered every 3 weeks with or without parenteral iron in anemic subjects with nonmyeloid malignancies receiving chemotherapy [abstract]. J Clin Oncol 2006;24(suppl):8612.
35. Henry DH, Dahl NV, Auerbach M, et al. Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist 2007;12:231-42.
36. Bellet RE, Ghazal H, Flam M, et al. A phase III randomized controlled study comparing iron sucrose intravenously (IV) to no iron treatment of anemia in cancer patients undergoing chemotherapy and erythropoietin stimulating agent (ESA) therapy. Proc Am Soc Clin Oncol 2007;25:9109.